SCHEMBL1580903

SCHEMBL1580903

O=C1NC(=O)C(=Cc2cc(C(F)(F)F)cc(Cl)c2N2CCC(N3CCCC3)CC2)S1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PIM2 Q9P1W9 8/20 0.46
▸ PIM1 P11309 7/20 0.45
▸ PIM3 Q86V86 5/20 0.45
▸ NR1H4 Q96RI1 1/20 0.41
▸ TTR P02766 1/20 0.40
▸ CISD1 Q9NZ45 1/20 0.40
▸ ESRRA P11474 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ HPGD P15428 5/20 0.40
▸ PTPN1 P18031 2/20 0.39
▸ PTPN2 P17706 1/20 0.39
▸ PTPN6 P29350 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ PIK3CD O00329 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12282081 1.00 PIM2 (0.46) PIM2PIM1PIM3NR1H4TTR
SCHEMBL1580902 1.00 PIM2 (0.46) PIM2PIM1PIM3NR1H4TTR
SCHEMBL2418591 0.99 PIM2 (0.46) PIM2PIM1PIM3NR1H4TTR
SCHEMBL2418589 0.99 PIM2 (0.46) PIM2PIM1PIM3NR1H4TTR
SCHEMBL12281659 0.99 PIM2 (0.46) PIM2PIM1PIM3NR1H4TTR
SCHEMBL1581223 0.92 PIM2 (0.45) PIM2PIM1PIM3NR1H4TTR
SCHEMBL1581225 0.92 PIM2 (0.45) PIM2PIM1PIM3NR1H4TTR
SCHEMBL12282075 0.92 PIM2 (0.45) PIM2PIM1PIM3NR1H4TTR
SCHEMBL1580670 0.92 PIM2 (0.44) PIM2PIM1PIM3NR1H4TTR
SCHEMBL1580671 0.92 PIM2 (0.44) PIM2PIM1PIM3NR1H4TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 — — US claimed
JP-2011526616-A — — 2011-10-13 — — JP claimed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 — — US claimed
EP-2310010-A2 CHEMICAL COMPOUNDS 251 AstraZeneca AB (SE) 2011-04-20 — — EP claimed
WO-2010001169-A2 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2010-01-07 — — WO claimed
US-20150051185-A1 Chemical Compounds 251 ASTRAZENECA AB (SE) 2015-02-19 — — US disclosed
US-8901307-B2 Chemical compounds 251 ASTRAZENECA AB (SE) 2014-12-02 — — US disclosed
US-20110218182-A1 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2011-09-08 — — US disclosed
EP-2310010-A2 CHEMICAL COMPOUNDS 251 AstraZeneca AB (SE) 2011-04-20 — — EP disclosed
WO-2010001169-A2 CHEMICAL COMPOUNDS 251 ASTRAZENECA AB (SE) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218182-A1 CHEMICAL COMPOUNDS 251 PIM1, PIM3, PIM2 PIM2 3/4885PIM1 1/4885PIM3 2/4885
US-20150051185-A1 Chemical Compounds 251 PIM1, PIM3, PIM2 PIM2 3/4885PIM1 1/4885PIM3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback